The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Further strengthens BaseLaunch's global pharma industry partnerships
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Subscribe To Our Newsletter & Stay Updated
